Zacks Investment Research on MSN

Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?

Vertex Pharmaceuticals Incorporated VRTX stock has risen 9.2% in the past three months. However, the stock has significantly ...
Nasdaq

Vertex Energy (VTNR) Upgraded to Buy: What Does It Mean for the Stock?

Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Seeking Alpha

Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape

Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using ...

Check Out What Whales Are Doing With VRTX

With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be ...
FierceBiotech

Vertex inches closer to acute pain market with FDA application acceptance

Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor ...
Barchart on MSN

Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals Incorporated (VRTX), based in Boston, Massachusetts, is a prominent biotech firm specializing in the ...
AOL

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...
FierceBiotech

Vertex drops aspiring Journavx follower in acute pain after phase 2 failure

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...
Nasdaq

This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatment -- and it expects to hold that title until at least the late 2030s. There's a lot to love about the company's ...
The Motley Fool

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel. There ...
Washington Technology

How Vertex Aerospace has charted its next path

Vertex Aerospace has at various points been a standalone company, a business unit within another large defense market player, and more recently back to being a standalone company. Its CEO explains to ...
The Motley Fool

This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon

The cystic fibrosis specialist is moving into other lucrative areas. The biotech company may be about to prove that, yes, it can. Vertex CEO Reshma Kewalramani made a statement about one of the ...